Active — Not RecruitingPhase 1

A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants

Japan32 participantsStarted 2026-03-13

Plain-language summary

The purpose of the study is to assess the effect of AZD5004 on the pharmacokinetics (PK) of mitiglinide and pioglitazone in healthy participants.

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Clinically significant inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper gastrointestinal (GI) tract
✕. Cardiovascular disease
✕. Neuromuscular or neurogenic disease
✕. Type 1 or type 2 diabetes mellitus

Area under concentration-time curve from time 0 to infinity (AUCinf)

Timeframe: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70

Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

Timeframe: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70

Maximum observed drug concentration (Cmax)

Timeframe: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70

NCT IDNCT07444424

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-07-02